drugset / Trial / NCT05661344

A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Liver Problems

NCT05661344

Phase 1 Completed 28 enrolled Boehringer Ingelheim
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is open to adults aged 18 years and older. People without liver problems and people who have mild or moderate liver problems can join the study. The purpose of this study is to find out how a medicine called BI 1015550 is taken up in the blood of people with and without liver problems. Liver problems may change how a medicine is processed in the body. Participants are in the study for about 2 weeks. During this time, they visit the study site 6 times. On the second visit, participants stay overnight at the study site for 4 nights. At the visits, doctors take blood samples to measure the levels of BI 1015550 in participants' blood. Then they compare the results between the groups of participants with and without liver problems. The doctors also check participants' health and take note of any unwanted effects.

Timeline

Start
2023-02-07
Primary completion
2023-09-13
Completion
2023-09-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Nerandomilast Small molecule 18 mg Oral

Indications